Latest Breaking News On - Trophic communications - Page 1 : vimarsana.com

ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024

MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results And New Data Reinforcing Strategic Focus In Kidney Disease

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"

Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. , a clinical stage...

Immatics Announces First Quarter 2024 Financial Results and Business Update

MaaT Pharma : Inside Information / News release on accounts, results

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024